Organization & Developments: PhaseBio

Parents

2019: PhaseBio Pharmaceuticals (PHAS) _A $4 Biotech Stock Worthy Of ‘Watch Item’ Status_gallery.mailchimp.com
2019: PhaseBio Pharmaceuticals: One Wild Ride For Shareholders Since Debut_seekingalpha.com
2019: PhaseBio's Latest FDA Designation Moves It One Step Closer To Potential Approval_seekingalpha.com
2020: PhaseBio Provides Pemziviptadil (PB1046) Program Update
2021: PhaseBio: Interesting Platform With Additive Value, Low On Cash
PhaseBio is focused primarily on diabetes, cardiovascular issues and metabolic disease.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications.